4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection
Key Takeaways
- Antibiotic colitis is enumerated under colonic and anorectal disease, while nosocomial and procedure- or device-associated infections are separate blueprint subsections.
- Only diarrheal stool should be tested for Clostridioides difficile, because testing formed stool detects colonization rather than disease.
- Fulminant disease with hypotension, ileus or megacolon requires combined oral and intravenous therapy plus urgent surgical consultation.
- Fecal microbiota-based therapy is used for multiply recurrent rather than first-episode infection.
- Catheter removal is mandatory for bloodstream infection due to Staphylococcus aureus, Candida species, Pseudomonas, or when there is tunnel infection, septic thrombosis or persistent bacteremia.
1. Clostridioides difficile Infection (CDI)
Clostridioides difficile is an anaerobic, spore-forming, toxin-producing Gram-positive bacillus that is the leading cause of healthcare-associated infectious diarrhea.
Pathogenesis & Risk Factors
- Microbiota Disruption: Exposure to broad-spectrum antimicrobials (Clindamycin, Fluoroquinolones, 3rd/4th generation Cephalosporins, Carbapenems) disrupts normal anaerobic colonic flora, allowing ingested spores to germinate into vegetative bacilli.
- Toxins: Production of Toxin A (enterotoxin) and Toxin B (cytotoxin) causes actin depolymerization, mucosal inflammation, epithelial cell necrosis, and the formation of characteristic inflammatory pseudomembranes composed of neutrophils, mucin, and cellular debris.
- Risk Factors: Recent antibiotic use (within past 90 days), advanced age (>=65 years), hospitalization, proton pump inhibitor (PPI) therapy, chronic kidney disease, and gastrointestinal surgery.
Diagnostic Testing Strategy
- Who to Test: Only test patients with unexplained, new-onset diarrhea (>=3 unformed stools in 24 hours). Never test asymptomatic patients (high rate of asymptomatic colonization).
- Laboratory Algorithm:
- Multi-step testing combines Glutamate Dehydrogenase (GDH) antigen screening (high sensitivity) or NAAT / PCR for toxin genes with Enzyme Immunoassay (EIA) for Toxins A and B (high specificity).
GDH (+) / Toxin EIA (+)confirms active, toxin-producing C. difficile disease.GDH (+) / Toxin EIA (-)represents either low toxin levels or asymptomatic colonization; clinical correlation or reflex PCR is required.
Staging and Management (IDSA/SHEA Guidelines)
| Clinical Category | Clinical & Laboratory Criteria | Preferred First-Line Treatment | Alternative Regimens |
|---|---|---|---|
| Initial Episode: Non-Severe | • WBC count <= 15,000/mcL AND<br/>• Serum Creatinine < 1.5 mg/dL | • Oral Fidaxomicin 200 mg PO BID for 10 days (preferred due to lower recurrence rates) | • Oral Vancomycin 125 mg PO QID for 10 days.<br/>(Oral Metronidazole is no longer recommended as first-line therapy). |
| Initial Episode: Severe | • WBC count > 15,000/mcL OR<br/>• Serum Creatinine >= 1.5 mg/dL | • Oral Fidaxomicin 200 mg PO BID for 10 days | • Oral Vancomycin 125 mg PO QID for 10 days. |
| Fulminant CDI | • Hypotension, septic shock, ileus, or toxic megacolon (colonic diameter >6 cm with systemic toxicity) | • High-Dose Oral Vancomycin 500 mg PO (or via NG tube) QID PLUS<br/>• IV Metronidazole 500 mg IV every 8 hours.<br/>• If ileus is present: Add Vancomycin Rectal Enema (500 mg in 100 mL normal saline per rectum q6h as retention enema).<br/>• Emergent Surgical Consultation for diverting loop ileostomy with colonic vancomycin lavage or subtotal colectomy. | N/A (medical emergency requiring dual/triple therapy plus surgical consult). |
| First Recurrence | • Recurrence of symptoms within 2–8 weeks of completing therapy | • If Vancomycin was used for initial episode: Oral Fidaxomicin 200 mg BID x 10 days.<br/>• If Fidaxomicin was used initially: Tapered and pulsed Oral Vancomycin regimen.<br/>• Consider adding Bezlotoxumab (monoclonal antibody against Toxin B; 10 mg/kg IV single infusion; use with caution in congestive heart failure). | • Tapered/pulsed Vancomycin (125 mg QID x 10-14d, BID x 7d, daily x 7d, then every 2-3 days for 2-8 weeks). |
| Second or Subsequent Recurrence (>=2 Recurrences) | • Multiple failed courses of standard antimicrobial regimens | • Fecal Microbiota Transplantation (FMT) delivered via colonoscopy or retention enema OR<br/>• FDA-Approved Live Biotherapeutic Products: Vowst (oral fecal microbiota spores live-brpk capsules) or Rebyota (fecal microbiota live-jslm rectal suspension) administered after completing antibiotic course. | • Prolonged oral Vancomycin taper followed by oral Rifaximin chaser. |
2. Catheter-Related Bloodstream Infections (CRBSI)
Central line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI) represent major sources of hospital-acquired bacteremia and septic shock.
Pathogenesis & Microbiology
- Extraluminal Route (<2 weeks of placement): Skin microorganisms migrate along the external catheter surface into the bloodstream.
- Intraluminal Route (>2 weeks of placement): Contamination of the catheter hub, connectors, or IV infusate leading to intraluminal biofilm colonization.
- Pathogens: Coagulase-Negative Staphylococci (30–40%), Staphylococcus aureus (MSSA/MRSA ~20%), Candida species (~10–15%), Enteric Gram-negative bacilli (Klebsiella, E. coli), and Pseudomonas aeruginosa.
Diagnostic Criteria for CRBSI
- Differential Time to Positivity (DTP): Blood cultures drawn simultaneously from the central venous catheter and a peripheral venipuncture show bacterial growth detected >=2 hours earlier in the catheter sample compared to the peripheral sample.
- Paired Quantitative Blood Cultures: A colony count >=3-fold higher from the catheter blood sample compared to the peripheral blood sample.
Central Venous Catheter Removal Indications
- Pathogen-Specific Indications: Catheter removal is mandatory for infections caused by: Staphylococcus aureus, Candida species, Pseudomonas aeruginosa, multi-drug resistant Gram-negative bacilli, or Mycobacterium spp.
- Complications of Infection: Septic shock, hemodynamic instability, suppurative thrombophlebitis, endocarditis, metastatic seeding (e.g., osteomyelitis), or persistent bacteremia >72 hours after initiation of active antimicrobial therapy.
- Local Signs: Severe tunnel infection or port pocket abscess.
Management Rules for Specific Pathogens
- Staphylococcus aureus Catheter Infection: Always remove the catheter. Minimum 2 weeks of IV bactericidal therapy (Cefazolin for MSSA, Vancomycin/Daptomycin for MRSA) is required for uncomplicated bacteremia (criteria: catheter removed, negative follow-up blood cultures at 48–72 hours, no prosthetic material, normal defervescence <72 hours, and transesophageal echocardiogram [TEE] negative for endocarditis). If any criterion is unmet, treat for 4 to 6 weeks.
- Candida Catheter Infection: Always remove the catheter. Initiate an Echinocandin (Caspofungin 70 mg load then 50 mg daily, Micafungin 100 mg daily, or Anidulafungin) for 14 days after the first negative blood culture. Mandatory step: Perform a dilated funduscopic ophthalmologic examination in all patients with candidemia within the first week to rule out Candida endophthalmitis.
A 74-year-old woman hospitalized for severe diverticulitis treated with intravenous Piperacillin-tazobactam for 10 days develops severe watery diarrhea with 10 bowel movements per day, severe cramping abdominal pain, and nausea. On physical examination, she is lethargic, her abdomen is markedly distended and tympanitic with diffuse tenderness and sluggish bowel sounds. Vital signs: blood pressure 84/50 mmHg on norepinephrine infusion, heart rate 128 bpm, and temperature 39.0°C (102.2°F). Laboratory evaluation reveals a WBC count of 38,000/mcL with 20% bands, serum creatinine of 2.8 mg/dL (baseline 0.9 mg/dL), and serum lactate of 3.8 mmol/L. Stool NAAT and toxin enzyme immunoassay are positive for Clostridioides difficile. Abdominal CT demonstrates marked pancolonic wall thickening, mucosal hyperemia, and colonic dilation measuring 7.5 cm in the cecum without free air. What is the most appropriate next step in management?
A 58-year-old man undergoing chemotherapy for acute myeloid leukemia via a right subclavian tunneled central venous catheter develops rigors and a temperature of 39.2°C (102.6°F). Physical examination reveals a clean catheter exit site without tunnel erythema or purulence. Blood cultures drawn from both the central catheter and a peripheral vein grow Methicillin-Susceptible Staphylococcus aureus (MSSA). Follow-up blood cultures at 48 hours remain positive. Which of the following represents the most appropriate management strategy?